Mar 27 |
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
|
Mar 7 |
Vaxxinity gains after early-stage data for Parkinson’s disease drug
|
Mar 7 |
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
|
Feb 15 |
Vaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levels
|
Feb 15 |
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
|
Feb 13 |
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
|
Jan 30 |
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases
|
Jan 30 |
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
|
Jan 19 |
Vaxxinity & UCF to Collaborate on Space Medicine Research
|
Jan 18 |
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
|